GlaxoSmithKline Pharmaceuticals P/B Ratio
GlaxoSmithKline Pharmaceuticals (GLAXO) P/B ratio is 19.06 (High), book value per share ₹134.14 vs Healthcare average P/B of -0.31 — Very High - Significant premium, high growth expectations or speculative. For live price, earnings yield and the full fundamental profile, see GlaxoSmithKline Pharmaceutical stock price NSE.
Current Valuation Metrics
Book Value Breakdown (2026)
Valuation Signal
Sector Context
GLAXO P/B Ratio — Valuation Insights & Book Value Analysis
GlaxoSmithKline Pharmaceuticals price-to-book ratio interpretation, valuation status and historical context — current P/B 19.06 (High). Review GLAXO P/E ratio to evaluate earnings-based valuation against sector peers.
- Stock appears overvalued with PB of 19.06, trading at significant premium to book value
- Trading at high premium to book value - indicates strong growth expectations or asset-light business model
- Trading at premium to sector average PB of -0.31
GlaxoSmithKline Pharmaceuticals P/B Ratio Historical Trend
GLAXO annual price-to-book ratio — 5 years, book value per share and year-end price. P/B below 1.0 indicates the stock trades below net asset value. View GlaxoSmithKline Pharmaceutical yearly highs lows for the annual high/low range and current price position.
GLAXO Historical P/B Ratio — Book Value Per Share & Year-End Price
GlaxoSmithKline Pharmaceuticals annual P/B ratio, book value per share (₹), year-end price and total equity in ₹ Crores.
| Year | P/B Ratio | Book Value/Share (₹) | Year-end Price (₹) | Total Equity (₹ Cr) | Valuation |
|---|---|---|---|---|---|
| 2026 | 18.74 | ₹134.14 | ₹2514.30 | ₹2,267 | High |
| 2025 | 21.43 | ₹115.44 | ₹2473.60 | ₹1,951 | High |
| 2024 | 21.4 | ₹105.21 | ₹2251.85 | ₹1,778 | High |
| 2023 | 18.43 | ₹103.02 | ₹1898.15 | ₹1,741 | High |
| 2022 | 8.37 | ₹157.57 | ₹1318.75 | ₹2,663 | High |
GLAXO vs Healthcare Peers — P/B Ratio Comparison
GlaxoSmithKline Pharmaceuticals P/B 19.06 vs Healthcare average -0.31, median 0.57 — range -14.47–1.1.
| Company | Symbol | P/B Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Rekvina Laboratories | VINRKLB | -14.47 | ₹18 | Low |
| Span Divergent | SDL | -6.32 | ₹19 | Low |
| Parmax Pharma | PARMAX | -5.61 | ₹39 | Low |
| Oxygenta Pharmaceutical | OXYGENTAPH | -5.54 | ₹203 | Low |
| Satiate Agri | SATAGRI | -3.39 | ₹8 | Low |
| Adline Chem Lab | ADLINE | -3.03 | ₹5 | Low |
| Bharat Immunologicals | BIBCL | -2.22 | ₹72 | Low |
| Krebs Biochemicals & Ind… | KREBSBIO | -0.71 | ₹115 | Low |
| Cresanto Global | CRESANTO | -0.7 | ₹2 | Low |
| Vivimed Labs | VIVIMEDLAB | -0.5 | ₹44 | Low |